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Objectives To assess trends in quinolone susceptibility of Enterobacteriaceae isolated in a large university
hospital.
Methods Between 1992 and 1998, bacterial isolates were collected each year during a 3-month period to
evaluate annual changes in susceptibility. In addition, the activities of fluoroquinolones (pefloxacin,
norfloxacin, ofloxacin, ciprofloxacin) against nalidixic acid-resistant strains were determined by disk diffusion
and MIC methodologies during the first and last year of the study.
Results The susceptibility of Enterobacteriaceae to nalidixic acid was unchanged between 1992 and 1998
(86% versus 85%). However, at the species level, the susceptibility rates to nalidixic acid decreased for
Escherichia coli from 92% to 89%, and for Enterobacter cloacae from 87% to 82%. In contrast, there was a 10%
increase in the nalidixic acid susceptibility rates for Klebsiella pneumoniae (74% versus 83%), which was
thought to be due to the control of the spread of epidemic extended-spectrum b-lactamase
(ESBL)-producing strains. The overall susceptibility of the Enterobacteriaceae to the fluoroquinolones
remained high during the study period, greater than 90% in the case of ciprofloxacin. However, nalidixic
acid-resistant Escherichia coli showed decreased susceptibility to ciprofloxacin between 1992 and 1998, as
reflected by a decrease in median zone diameter (26 mm to 19 mm), an increase in MIC50 (0.25 mg/L to
1 mg/L) and a shift in MIC distribution (unimodal in 1992 to bimodal in 1998). This has resulted in the
reduced susceptibility of Escherichia coli to fluoroquinolones between 1992 and 1998 (pefloxacin, 95–90%;
ciprofloxacin, 99–95%).
Conclusions The susceptibility of Escherichia coli to quinolones has decreased, and the level of susceptibility of
the resistant strains has increased over the 7-year study period.
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INTRODUCTION
Quinolones, including nalidixic acid and its derivatives such as
pipemidic acid, oxolinic acid and flumequine, have been largely
used for many years in the treatment of urinary tract infections
on the basis of their activity against Enterobacteriaceae. The
fluoroquinolones developed in the 1980s, pefloxacin, norflox-
acin, ofloxacin and ciprofloxacin, have improved potency
against Enterobacteriaceae, and for some of them the spectrum
of activity extends to other Gram-negative species such as
Pseudomonas aeruginosa or to Gram-positive species such as
staphylococci. Because of this broad spectrum of activity and
a favorable pharmacokinetic profile, including good oral bioa-
vailability, fluoroquinolones are now widely used to treat
community- and hospital-acquired infections.
In the years following the introduction of fluoroquinolones, a
decrease in susceptibility was reported for Staphylococcus aureus
[1,2] and Pseudomonas aeruginosa [3–5]. Meanwhile, the suscept-
ibility of Enterobacteriaceae, especially Escherichia coli, did not
change significantly [3,4]. There is a paucity of data available on
the quinolone susceptibility of aerobic Gram-negative bacilli
[6,7], and the data are often limited to a particular species such as
Escherichia coli [8–10] or to a particular drug such as ciproflox-
acin [7,8,11].
We assessed trends in the susceptibility of Enterobacteriaceae
to quinolones in a large university hospital by performing
3-month period prevalence surveys over a 7-year period of
time. In order to identify slight changes in the level of suscept-
ibility to fluoroquinolones, and to evaluate the degree of
cross-resistance between old and new quinolones, we measured
fluoroquinolone MICs against the strains resistant to nalidixic
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acid. Finally, we investigated the degree of association between
resistance to quinolones and resistance to antimicrobials other
than quinolones.
MATERIALS AND METHODS
Setting
Pitie´-Salpeˆtrie`re Hospital is a 2200-bed tertiary-care university
hospital including all medical and surgical subspecialities,
accounting for a mean of 55 000 admissions per year. There
were no guidelines regarding the use of antimicrobials during
the study period.
Design
To assess trends over time of quinolone susceptibility, we
performed a period prevalence survey during a 3-month period
(August to October) in 1992 as baseline, and yearly from 1995
to 1998. All consecutive strains of Enterobacteriaceae isolated
during the five period prevalence surveys were included in the
study. Only strains isolated from clinical specimens originating
from inpatients were included. Identification to the species level
was routinely performed by standard methods using the API
20E system (BioMe´rieux, la Balme les Grottes, France). Strains
of the same species with a similar antibiotic susceptibility pattern
and isolated from the same patient were considered as duplicates
and were included only once in the study.
Susceptibility testing
The disk diffusion method was used for antibiotic susceptibility
testing. Mueller–Hinton agar and disks of antibiotics were
purchased from Sanofi Diagnostics Pasteur (Marne la Coquette,
France) and were used according to the guidelines of the
Antibiogram Committee of the French Society for Microbiol-
ogy (CA-SFM).
Susceptibility to quinolones was evaluated using zone dia-
meter breakpoints of 20 mm for nalidixic acid, and 22 mm for
pefloxacin, ofloxacin, and ciprofloxacin, which correspond to
MICs of 8 and 1 mg/L, respectively. All non-susceptible strains
were categorised as resistant.
We compared the distributions of nalidixic acid and cipro-
floxacin inhibition zone sizes (zone diameter, D) in 1992 and
1998 in order to assess changes in population clustering at the
start and at the end of the study period.
Susceptibility to b-lactams was evaluated using patterns
previously defined, i.e. wild-type pattern and acquired resis-
tance patterns. Extended-spectrum b-lactamases (ESBLs) were
detected by using the synergy test as described previously [12].
Gentamicin was used to evaluate the susceptibility to amino-
glycosides (breakpoint of 16 mm, 4 mg/L). Susceptibility to
sulfamethoxazole–trimethoprim was evaluated by using the
zone diameter breakpoint of 16 mm (2/38 mg/L).
For the nalidixic acid-resistant strains isolated in 1992 and in
1998, MICs of four fluoroquinolones were determined by the
agar dilution method on Mueller–Hinton agar by using a Steers
replicator device delivering 104 CFU/spot. Pefloxacin (Roger
Bellon, Paris, France), ofloxacin (Roussel, Paris, France) and
ciprofloxacin (Bayer Pharma, Puteaux, France) were kindly
provided by the manufacturers, and norfloxacin was purchased
from Sigma (Saint Quentin Fallavier, France). Wild-type strains
(i.e. nalidixic acid susceptible) isolated during the same period
of time as the nalidixic acid-resistant strains were used as
controls for each species. Escherichia coli ATCC 25922, Enter-
obacter cloacae ATCC 13047 and Klebsiella pneumoniae ATCC
10031 were included as reference strains. Percentages of sus-
ceptibility were interpreted according to CA-SFM and NCCLS
recommendations.
Statistical analysis
The chi-square test or Fisher’s exact test was used to compare
proportions. The chi-square test for linear trend was used to
assess trends over time. Time trends were assessed only when
there were at least 20 isolates per each 3-month period. All tests
were two-sided and the level of statistical significance was set at
0.05.
RESULTS
Overall, 8162 strains of Enterobacteriaceae were included in the
study. The predominant species were Escherichia coli (59%),
Proteus mirabilis (9%) and K. pneumoniae (9%). The distribution
of bacterial species in medical and surgical units was similar,
with Escherichia coli accounting for 63% and 59% of the isolates,
respectively. In contrast, Escherichia coli represented only 42% of
the isolates in the intensive care unit (ICU), and the proportion
of Enterobacter cloacae and Serratia spp. was higher than in other
wards. Urines accounted for 70% of the total of the specimens,
lower respiratory tract specimens 4%, and blood 5%. Other
specimens included mainly surgical wounds, intravascular
catheters and pus. Urine and blood specimens were provided
in similar proportions by medical and surgical units. Respira-
tory tract specimens, wounds and catheters originated princi-
pally from ICUs. There were no trends in species distribution
within each type of unit and within each type of specimen
between 1992 and 1998.
Susceptibility to nalidixic acid
The rates of susceptibility to nalidixic acid of the main species
are presented in Table 1. Overall, 85% of the strains were
susceptible to nalidixic acid. The species that were most often
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susceptible were K. oxytoca (94%), Escherichia coli (89%), and
other species, including Citrobacter koseri (91%) and Morganella
morganii (90%), whereas Serratia spp. (60%), Enterobacter cloacae
(78%) and Proteus mirabilis (78%) were the least often susceptible.
There was no statistically significant difference in the rates of
susceptibility to nalidixic acid among Escherichia coli strains
isolated from urines (89%), blood (91%), and the respiratory
tract (92%). In contrast, strains of Proteus mirabilis, Enterobacter
cloacae and K. pneumoniae isolated from blood were more
susceptible to nalidixic acid (range, 80–88%) than those isolated
from urines (range, 73–77%). The overall rate of susceptibility
to nalidixic acid in Enterobacteriaceae was slightly lower for
strains isolated in ICUs (82%) than for those isolated in medical
(85%; P¼ 0.03) and in surgical wards (86%; P< 0.01). K.
pneumoniae strains isolated in ICUs were less frequently suscep-
tible to nalidixic acid (69%) than strains isolated in medical
(81%; P¼ 0.08) and surgical wards (80%; P¼ 0.02). There was
no difference in Escherichia coli susceptibility rates by type of unit
(89–91%).
Susceptibility to fluoroquinolones
As expected, the rates of susceptibility to fluoroquinolones were
higher than those to nalidixic acid (Table 1). Overall, a higher
proportion of strains was susceptible to ciprofloxacin (93%) than
to pefloxacin (88%). The difference between the rates of
susceptibility to ciprofloxacin and pefloxacin was greater among
species with low rates of susceptibility to nalidixic acid, such as
K. pneumoniae (91% versus 79%), Enterobacter cloacae (85% versus
79%), and Serratia spp. (73% versus 60%), than among species
with high rates of susceptibility to nalidixic acid, such as
Escherichia coli (96% versus 92%) and M. morganii (97% versus
91%).
Time trends from1992 to 1998
During the study period, there was no time trend in the rate of
susceptibility to nalidixic acid for Enterobacteriaceae taken as a
whole (Table 1). However, at the species level, there was a slight
downward trend in the rate of susceptibility to nalidixic acid for
Escherichia coli (92% in 1992 versus 89% in 1998; P¼ 0.003) and
Enterobacter cloacae (87% versus 82%; P¼ 0.01). For the latter
species, the lowest rate of susceptibility was observed in 1997
(66%). In contrast, there was an upward trend in the rate of
susceptibility for K. pneumoniae from 1992 (74%) to 1996 (83%;
P¼ 0.001), the rates remaining steady thereafter. For the
other species, the rates remained steady throughout the study
period.
There was a slight downward trend from 1992 to 1998 in the
overall rate of susceptibility to pefloxacin (89% versus 87%,
respectively; P¼ 0.06) and ciprofloxacin (96% versus 92%,
respectively; P< 0.001). At the species level (Table 1), trendsTa
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over time were similar to those observed with nalidixic acid:
downward trends for Escherichia coli and Enterobacter cloacae, and
an upward trend for K. pneumoniae. A downward trend was
observed for Escherichia coli strains isolated from urinary speci-
mens but not for those isolated from non-urinary specimens. In
1998, 44% of ciprofloxacin-resistant Escherichia coli strains were
of nosocomial origin (isolated >48 h after admission).
Population analysis based on the disk diffusionmethod
(1992 versus 1998)
When considering Enterobacteriaceae as a whole, zone dia-
meter distribution patterns for nalidixic acid displayed a bimo-
dal distribution in 1992 and in 1998. The median zone diameter
of the susceptible population (D¼ 20 mm) was similar in 1992
(25 mm, range 20–35) and in 1998 (26 mm, range 20–35). The
intermediate zone (16D 19 mm) accounted for only 1.1%
of the entire population in 1992 and 0.6% in 1998. For a vast
majority of the resistant strains (D< 16 mm), there was no
inhibition zone (84% in 1992, 89% in 1998).
When considering Escherichia coli (Figure 1a), the distribution
patterns for nalidixic acid were also similar in 1992 and 1998.
There was no change in the median zone diameter, either for
the susceptible population (26 mm in 1992 versus 27 mm in
1998), or for the resistant population (no inhibition zone, in
1992 and 1998). The distribution patterns of ciprofloxacin zone
diameters remained unchanged for Escherichia coli strains sus-
ceptible to nalidixic acid (median, 35 mm for both years) but
changed markedly for nalidixic acid-resistant strains (Figure 1b).
Indeed, for the latter strains, the median and the mode were,
respectively, 28 mm and 28 mm in 1992 but 19 mm and 6 mm
(no inhibition zone) in 1998. As a consequence, the proportions
of nalidixic acid-resistant strains of Escherichia coli that were
susceptible, intermediate and resistant to ciprofloxacin were
93%, 4% and 3% in 1992, but 47%, 3% and 50% in 1998,
respectively.
Figure 1 Distribution (%) of the inhibition
zone diameters for nalidixic acid against all Es-
cherichia coli strains (a) and for ciprofloxacin
against Escherichia coli strains resistant to nali-
dixic acid (b).
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Susceptibility to fluoroquinolones in nalidixic acid-resistant
strains
Among all strains of Enterobacteriaceae resistant to nalidixic
acid by the disk diffusion method, 192 of the 220 strains isolated
in 1992, and 209 of the 220 strains isolated in 1998, were
available for MIC determination. Geometric mean MIC,
MIC50 and MIC90 of the four fluoroquinolones are presented
in Table 2.
For all species, MICs were always the highest for pefloxacin
and the lowest for ciprofloxacin. When compared to wild-type
strains tested as controls, the nalidixic acid-resistant strains
displayed a clear increase in MICs against all four fluoroqui-
nolones. MIC50s and geometric mean MICs of pefloxacin,
norfloxacin and ofloxacin were above the susceptibility break-
points recommended by the CA-SFM and NCCLS. A majority
of the strains resistant to nalidixic acid were not susceptible to
these three fluoroquinolones. In contrast, a majority (77% in
1992, and 58% in 1998) were still susceptible to ciprofloxacin
despite a marked increase in MICs when compared to those
found against wild-type strains.
The MICs of the four fluoroquinolones against nalidixic
acid-resistant strains of Escherichia coli increased markedly from
1992 to 1998. Consequently, the proportion of strains which
were still susceptible to the four fluoroquinolones decreased
significantly from 1992 to 1998. In fact, the MIC distribution
pattern (Figure 2a) was unimodal in 1992 (mode for cipro-
floxacin: 0.25 mg/L), but bimodal in 1998 (modes for cipro-
floxacin: 0.12 mg/L and 8 mg/L). Thus, a new subpopulation
resistant to fluoroquinolones (MIC> 2 mg/L) was found in
1998 compared to 1992.
In contrast, the MICs of the four fluoroquinolones against
nalidixic acid-resistant K. pneumoniae were slightly but signifi-
cantly lower in 1998 than in 1992. The MIC distribution
patterns remained bimodal (Figure 2b) but the mode of the
larger population was lower in 1998 than in 1992 (ciproflox-
acin, 0.25 mg/L versus 1 mg/L).
Fluoroquinolone MICs against species of Enterobacteriaceae
producing inducible chromosomal cephalosporinase (Enterobac-
ter spp., Serratia spp., C. freundii) were very close in 1992 and
1998, with bimodal distribution patterns (e.g. for ciprofloxacin
2 mg/L and 8 mg/L in 1992, and 1 mg/L and 8 mg/L in 1998).
However, considering separately Enterobacter cloacae, the MIC50
increased from 8 mg/L to 64 mg/L for pefloxacin, 2 mg/L to
32 mg/L for ofloxacin, and 1 mg/L to 16 mg/L for ciproflox-
acin in 1992 and 1998, respectively.
Association of resistance between quinolones and non-quinolone
antimicrobials
Resistance to quinolones was frequently associated with acquir-
ed resistance to b-lactams, aminoglycosides or co-trimoxazole
(Table 3). Indeed, 68% of the nalidixic acid-resistant strains had
a pattern of acquired resistance to b-lactams, compared to 31%
of the nalidixic acid-susceptible strains. It is of interest that all K.
pneumoniae strains with a pattern suggesting ESBL production
were resistant to nalidixic acid and mostly resistant to fluor-
oquinolones, including ciprofloxacin. The absolute number
and the proportion of such strains within this species decreased
significantly from 1992 to 1998 (29 of 167 strains to seven of
126 strains, respectively; P< 0.01 chi square for trend). Con-
sequently, the susceptibility of K. pneumoniae to quinolones
increased during the same period. Indeed, the proportion of
nalidixic acid-susceptible K. pneumoniae remained stable over
the entire study period (89% in 1992 to 88% in 1998; P¼ 0.49,
chi square for trend) when ESBL-producing K. pneumoniae
strains were excluded from the analysis.
Resistance of Enterobacteriaceae to quinolones was also
significantly associated with resistance to gentamicin (27% of
the nalidixic acid-resistant strains compared to only 2% of the
nalidixic acid-susceptible strains), and sulfamethoxazole–tri-
methoprim (81% of the nalidixic acid-resistant strains compared
to 30% of the nalidixic acid-susceptible strains).
Figure 2 Distribution (%) of the minimal inhibitory concentrations (MICs)
of ciprofloxacin against nalidixic acid-resistant Escherichia coli (a) and K.
pneumoniae (b).
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Table 2 In vitro activity of fluoroquinolones against nalidixic acid-resistant strains (MICs inmg/L)
%S2
Bacterial species (n) Years Range MIC50 MIC90
Geometric
meanMIC
(ratio S/Ra) CA-SFM NCCLS
All species
(1992, n¼192;
1998, n¼209)
Pefloxacin 1992 0.12 to>128 8 64 7.5 (30) 13 ^
1998 0.12 to>512 8 512 13.5 (82) 12 ^
Norfloxacin 1992 0.03 to>128 2 64 2.8 (31) 38 76
1998 0.03^512 4 512 5.9 (82) 34 56
Ofloxacin 1992 0.06^128 2 16 2.6 (19) 35 55
1998 0.03^128 2 32 3.1 (44) 37 53
Ciprofloxacin 1992 <0.015 to>128 1 32 1.1 (42) 77 77
1998 <0.015^256 1 32 1.3 (50) 58 58
Escherichia coli
(1992, n¼66;
1998, n¼100)
Pefloxacin 1992 0.25 to>128 2 8 2.2 (15) 27 ^
1998 0.12 to>512 16 512 14.8 (123) 16 ^
Norfloxacin 1992 0.06 to>128 0.5 2 0.6 (13) 88 98
1998 0.06^512 8 256 6.5 (127) 44 56
Ofloxacin 1992 0.12^64 1 2 0.9 (15) 79 97
1998 0.06^128 4 32 3.1 (65) 44 52
Ciprofloxacin 1992 <0.015^64 0.25 1 0.3 (38) 94 94
1998 <0.015^256 1 32 1.4 (175) 51 51
Klebsiella pneumoniae
(1992, n¼37;
1998, n¼20)
Pefloxacin 1992 2^128 8 32 10.4 (35) 0 ^
1998 1^16 4 8 2.9 (12) 20 ^
Norfloxacin 1992 1^32 2 16 3.4 (23) 5 89
1998 0.5^16 2 4 2.2 (15) 30 95
Ofloxacin 1992 0.5^16 4 8 3.3 (14) 8 81
1998 0.5^8 1 2 1.1 (9) 60 95
Ciprofloxacin 1992 0.25^16 1 8 1.5 (22) 60 60
1998 0.12^8 0.5 1 0.4 (6) 95 95
aRatio S/R, geometric meanMIC against nalidixic acid-resistant/susceptible strains.
b%S, percentage of strains susceptible according to CA-SFMor NCCLS breakpoints.
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DISCUSSION
In the present study conducted between 1992 and 1998 in a
large university hospital, we assessed trends in the susceptibility
to classical quinolones and fluoroquinolones by qualitative
(categorisation by breakpoints) and quantitative (distribution
of zone size diameters and MICs) methods. We showed a
decrease in the rate of susceptibility to nalidixic acid in Escher-
ichia coli and Enterobacter cloacae but an increase in K. pneumoniae.
Although the rate of susceptibility to fluoroquinolones
remained very high (i.e. >90% for ciprofloxacin), trends over
time paralleled those observed with nalidixic acid. In addition,
we showed that nalidixic acid-resistant Escherichia coli and
Enterobacter cloacae displayed an increase in the level of resistance
to fluoroquinolones.
Quinolone susceptibility of bacteria in a hospital setting has
been reported in several studies conducted in the early 1990s
[2,11,13–16] and differences have been noted according to
geographic areas or between sites within the same area
[2,14]. Hence, longitudinal studies conducted in the same
institutions are necessary to detect trends in susceptibility rates
over time. In a majority of these longitudinal studies, the
fluoroquinolone susceptibilities of most of the Enterobacter-
iaceae, and especially Escherichia coli, have remained steady
[2,6,11,17]. However, a decrease in susceptibility was observed
for nosocomial species such as Serratia spp., K. pneumoniae, C.
freundii and Pseudomonas aeruginosa [4,6,18]. Fluoroquinolone
resistance in Escherichia coli was rare, and in most of the long-
itudinal studies, resistance rates remained steady [2,6]. In a study
conducted from 1990 to 1996 in a Spanish hospital, Ena et al.
reported an increase in resistance to ciprofloxacin, from 3% to
20%, in Escherichia coli isolated from urinary tract infections, but
no increase among strains isolated from blood or other sites [8].
A similar finding has been reported in an earlier study, also
conducted in Spain in a general practice patient population [9].
Indeed, in 1983, 3% and 0% of Escherichia coli strains isolated
from urines were resistant, respectively, to pipemidic acid, a
classical quinolone, and to ciprofloxacin, as compared to 18%
and 7% in 1992. In a more recent study, Garau et al. reported the
emergence of quinolone-resistant Escherichia coli in patients with
nosocomial as well as community-acquired bacteremia [19]. In
the three latter studies, increase in resistance in Escherichia coli
followed a period of increased consumption of fluoroquino-
lones. It is noteworthy that the increase in resistance observed in
our hospital followed a period of high consumption of quino-
lones. Indeed, the consumption of fluoroquinolones increased
eight-fold in the pre-study period (from 4818 Defined Daily
Dose (DDD) in 1985 to 39 396 DDD in 1991), and then
remained at around 40 000 DDD per year. Since half of the
ciprofloxacin-resistant strains of Escherichia coli isolated in 1998
were recovered within the first 2 days of admission (generally
considered as community acquired), quinolone consumption in
the community also has to be implicated. Data from France
show that quinolone consumption in the community ac-
counted for 4.3% of the total number of patients treated with
antibiotics in 1991–92 compared to 2.9% in 1980–81, and that
the mean annual increase of fluoroquinolone consumption was
5.7% per year since 1985, higher than the general increase in
Table 3 Proportion of acquired resistance pattern to non-fluoroquinolone antimicrobials according to quinolone susceptibility in strains isolated in 1992
and1998
% acquired resistance patternb to:
Bacterial species (na) b-lactams Gentamicin Co-trimoxazole
Escherichia coli
Nalidixic acid susceptible (1665) 40 1 38
Nalidixic acid resistant (177) 63c 16c 79c
Proteus mirabilis
Nalidixic acid susceptible (217) 22 4 30
Nalidixic acid resistant (64) 78c 11d 75c
Klebsiella pneumoniae
Nalidixic acid susceptible (226) 26 2 17
Nalidixic acid resistant (65) 88c 29c 95c
Enterobacter cloacae
Nalidixic acid susceptible (171) 8 1 5
Nalidixic acid resistant (31) 68c 52c 84c
Total Enterobacteriaceae
Nalidixic acid susceptible (2712) 31 2 30
Nalidixic acid resistant (440) 68c 27c 81c
aData were missing for some strains.
bSee text for definitions.
cP<0.001, dP¼0.06, compared to the nalidixic acid-susceptible category.
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total antibiotic consumption [20]. It should be noted that the
relationship between antibiotic consumption and trends in
resistance found at a hospital level does not imply an unequi-
vocal causal relationship. However, more specific studies con-
ducted at the patient level (case–control studies) established that
quinolone administration was strongly associated with coloni-
sation or infection by a quinolone-resistant strain [19,21–25].
Enterobacter cloacae, which is almost exclusively a nosocomial
pathogen, was the only other Enterobacteriaceae species for
which the susceptibility rate to quinolones decreased. Suscept-
ibility to fluoroquinolones in this species was usually either
similar to, or slightly lower than, those of Escherichia coli in the
studies conducted in the early 1990s [2,6,13]. Low susceptibility
rates to quinolones among Proteus mirabilis and Serratia spp. have
already been reported in France [14,26], and in other parts of
the world [2,27,28].
In France, as well as in many other countries, clonal spread of
multiresistant K. pneumoniae producing ESBL was reported in
the late 1980s and the early 1990s [29]. These strains are, in
general, resistant to most antimicrobials, including aminoglyco-
sides, co-trimoxazole, classical quinolones, and most often
fluoroquinolones. As in the present study, high fluoroquinolone
resistance rates among K. pneumoniae were related to the epi-
demic of ESBL-producing strains that occurred in France
[14,26,30]. Between 1993 and 1997, a clear decrease in the
rate of ESBL strains was observed in Paris hospitals (including
our institution) as a consequence of a program aimed at limiting
cross-transmission of multidrug-resistant organisms [30].
Acquired resistance to quinolones results from the selection
of chromosomal mutants. In aerobic Gram-negative bacilli, the
main mechanism of resistance to quinolones is a mutation in
gyrA, one of the structural genes of the target DNA gyrase
[31,32]. This mechanism confers cross-resistance to nalidixic
acid and fluoroquinolones, but fluoroquinolone MICs against
single-step mutants generally remain lower than the breakpoints
[33–35]. Clinical resistance to fluoroquinolones generally
occurs through stepwise acquisition of gyrA and parC mutations
[35,36]. As expected, we showed that fluoroquinolone MICs
were significantly higher against nalidixic acid-resistant than
against nalidixic acid-susceptible strains, highlighting the cross-
resistance between classical quinolones and fluoroquinolones.
Distribution patterns of fluoroquinolone MICs against nalidixic
acid-resistant strains was bimodal, i.e. one subpopulation with a
low level of resistance and a second with a high level of
resistance. The appearance or the increase of the population
with a high level of fluoroquinolone resistance over time may be
the result of the selection of a subpopulation of multiple-step
mutants among strains with lower levels of resistance to fluor-
oquinolones. The present study emphasises the potential of
nalidixic acid for detecting abnormal patterns of susceptibility to
fluoroquinolones in Enterobacteriaceae [16]. Thus, it should be
reported as an indicator of a trend in fluoroquinolone resistance
in these bacteria. Reporting fluoroquinolone susceptibility
alone may be misleading, as a large proportion of Enterobac-
teriaceae with acquired resistance to classical quinolones remain
susceptible to fluoroquinolones according to CA-SFM or
NCCLS breakpoints, but they also exhibit significant increases
in MICs [16]. For the same reason, physicians should be aware
of resistance to classical quinolones in Enterobacteriaceae as
representing a risk of in vivo selection of mutants with a high
level of resistance to fluoroquinolones [32].
Resistance to quinolones was statistically associated with
resistance to unrelated antimicrobials (b-lactams, aminoglyco-
sides), as already described [14]. This combined resistance can
result from a decreased permeability of the cell wall or an
active efflux mechanism, which have been reported to lead
to unselective resistance to several antimicrobials, including
quinolones, b-lactams, tetracycline, trimethoprim, and chlor-
amphenicol [32,37]. The combined resistance can also result
from the sequential addition of different mechanisms of resis-
tance in the same strains [38–40]. Whatever the mechanism,
combined resistance is particularly worrisome from the ther-
apeutic point of view. It decreases the range of antimicrobials
that could be possibly used to treat patients infected with
multidrug-resistant organisms. It emphasises the need for mon-
itoring combined resistance when surveillance of resistance to
one particular drug is planned.
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